Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Champions Oncology's enterprise value is $74.38 Mil.
Champions Oncology's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was $0.35 Mil. Therefore, Champions Oncology's EV-to-EBITDA for today is 214.34.
The historical rank and industry rank for Champions Oncology's EV-to-EBITDA or its related term are showing as below:
CSBR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5046.3 Med: -1.56 Max: 1213.84
Current: 214.34
During the past 13 years, the highest EV-to-EBITDA of Champions Oncology was 1213.84. The lowest was -5046.30. And the median was -1.56.
CSBR's EV-to-EBITDA is ranked worse than 96.84% of 411
companies
in the Biotechnology industry
Industry Median: 12.05
vs CSBR: 214.34
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Champions Oncology (NAS:CSBR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Champions Oncology's PE Ratio (TTM) for today is calculated as:
Champions Oncology's share price for today is $5.37.
Champions Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Champions Oncology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Champions Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Champions Oncology's EV-to-EBITDA falls into.
Champions Oncology's current Enterprise Value is $74.38 Mil.
Champions Oncology's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology (CSBR) has a EV-to-EBITDA of 214.34 as of Aug. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Champions Oncology. According to the industry distribution chart, Champions Oncology ranks #398 out of 411 companies in the Biotechnology industry, placing it in the top 96.8%.
Is Champions Oncology's EV-to-EBITDA too high?
Champions Oncology's current EV-to-EBITDA is 214.34. The Biotechnology industry median EV-to-EBITDA is 12.05. Champions Oncology's value of 214.34 is 1678.8% above this industry median. Based on the distribution chart, Champions Oncology ranks #398 out of 411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's EV-to-EBITDA compare to RLYB and NRXS?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #398 out of 411 companies for EV-to-EBITDA. This places Champions Oncology in the lower half of its industry. The industry median EV-to-EBITDA is 12.05. Champions Oncology's value of 214.34 is 1678.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.05, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Champions Oncology's current EV-to-EBITDA of 214.34 is 1678.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Champions Oncology. For the Biotechnology industry, the median EV-to-EBITDA is 12.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Champions Oncology's current EV-to-EBITDA is 214.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.79, compared to a current price of $5.37 — trading 20.9% below its estimated fair value. The current EV-to-EBITDA is 214.34 and 1678.8% above the Biotechnology industry median of 12.05. Champions Oncology's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Champions Oncology (CSBR), the current EV-to-EBITDA is 214.34 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $5.37 is trading 20.9% below its estimated GF Value™ of $6.79.
GuruFocus considers Champions Oncology to be Modestly Undervalued.
Key valuation signals for CSBR:
EV-to-EBITDA: 214.34
GF Value™: $6.79 vs. price of $5.37 (20.9% below fair value)
Industry Position: 1678.8% above the Biotechnology median (#398 of 411)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
